19 May. 2022 18:00
Annual shareholders’ meeting
Q1 2022 SALES: €135M (UP 5.5% AS REPORTED, UP 2.2% AT CONSTANT EXCHANGE RATES) Q1 2022 ESSENTIALS...
April 2022
ALL FINANCIAL INDICATORS UP Annual sales: €521m (up 21.9% as reported) Essentials sales: €296m (up...
March 2022
Total Group Sales: €521 million (up 21.9% as reported) Annual Sale of Essential products: €296...
January 2022
Felpreva® (tigolaner/emodepside/praziquantel) has been granted marketing authorisation by the...
November 2021
Regarding dissolution of Vetoquinol Zenoaq Co., Ltd and establishment of Vetoquinol Japan Co., Ltd
Vetoquinol (Headquarters: Lure, France, CEO: Matthieu Frechin, hereafter Vetoquinol) and Nippon...
October 2021
Third quarter revenues: €132 million +14.3% at constant exchange rates
Third quarter sales of Essential products: €75 million +26.0% at constant exchange rates Vetoquinol...
October 2021
Vetoquinol UK achieves bronze accreditation with Investors in the Environment
Veterinary pharmaceuticals company, Vetoquinol UK, has achieved bronze accreditation with Investors...
October 2021
We are pleased to announce that the Committee for Medicinal Products for Veterinary Use (CVMP) has...
September 2021
